vTv Graps Logo.png
vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference
December 02, 2019 07:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Graps Logo.png
vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
October 30, 2019 17:30 ET | vTv Therapeutics Inc.
SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively enrolling HIGH POINT,...
vTv Graps Logo.png
vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
October 03, 2019 07:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing...
vTv Graps Logo.png
vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
September 18, 2019 07:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1...
vTv Graps Logo.png
vTv Therapeutics to Present Posters at Two Scientific Conferences in September
September 11, 2019 07:30 ET | vTv Therapeutics Inc.
 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program  HIGH POINT, N.C., Sept. 11, 2019 (GLOBE...
vTv Graps Logo.png
vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04, 2019 07:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
vTv Graps Logo.png
vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences 
August 06, 2019 16:05 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., Aug. 06, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered...
vTv Graps Logo.png
vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
July 31, 2019 16:30 ET | vTv Therapeutics Inc.
HIGH POINT, N.C., July 31, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019, and provided an update on...